BRPI0921596A2 - Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina - Google Patents

Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina

Info

Publication number
BRPI0921596A2
BRPI0921596A2 BRPI0921596A BRPI0921596A BRPI0921596A2 BR PI0921596 A2 BRPI0921596 A2 BR PI0921596A2 BR PI0921596 A BRPI0921596 A BR PI0921596A BR PI0921596 A BRPI0921596 A BR PI0921596A BR PI0921596 A2 BRPI0921596 A2 BR PI0921596A2
Authority
BR
Brazil
Prior art keywords
fluorofenoximethyl
piperidine
phenyl
components
Prior art date
Application number
BRPI0921596A
Other languages
English (en)
Inventor
D Long Daniel
Stangeçand Eric
Jean Patterson Lori
Zipfel Sheila
Original Assignee
Therevance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therevance Inc filed Critical Therevance Inc
Publication of BRPI0921596A2 publication Critical patent/BRPI0921596A2/pt
Publication of BRPI0921596B1 publication Critical patent/BRPI0921596B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
BRPI0921596-4A 2008-11-14 2009-11-13 Compostos de 4-[2-(2-fluorfenoximetil)fenil]piperidina, composição, método de preparação e uso relacionados BRPI0921596B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
US61/114,541 2008-11-14
PCT/US2009/064308 WO2010056941A1 (en) 2008-11-14 2009-11-13 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Publications (2)

Publication Number Publication Date
BRPI0921596A2 true BRPI0921596A2 (pt) 2018-03-20
BRPI0921596B1 BRPI0921596B1 (pt) 2021-10-26

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0921593A BRPI0921593B8 (pt) 2008-11-14 2009-11-13 processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionados
BRPI0921595A BRPI0921595B8 (pt) 2008-11-14 2009-11-13 sal monocloridrato cristalino de 4-[2,4,6-(trifluorfenoximetil)fenil]piperidina, seu processo de preparo e usos
BRPI0921596-4A BRPI0921596B1 (pt) 2008-11-14 2009-11-13 Compostos de 4-[2-(2-fluorfenoximetil)fenil]piperidina, composição, método de preparação e uso relacionados

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0921593A BRPI0921593B8 (pt) 2008-11-14 2009-11-13 processo para preparar compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina e compostos relacionados
BRPI0921595A BRPI0921595B8 (pt) 2008-11-14 2009-11-13 sal monocloridrato cristalino de 4-[2,4,6-(trifluorfenoximetil)fenil]piperidina, seu processo de preparo e usos

Country Status (29)

Country Link
US (22) US8247433B2 (pt)
EP (3) EP2358675B9 (pt)
JP (6) JP5529150B2 (pt)
KR (3) KR101685186B1 (pt)
CN (3) CN102216272B (pt)
AR (3) AR074128A1 (pt)
AU (3) AU2009313951B2 (pt)
BR (3) BRPI0921593B8 (pt)
CA (3) CA2742114C (pt)
CL (2) CL2011001088A1 (pt)
CO (2) CO6361988A2 (pt)
CY (3) CY1113622T1 (pt)
DK (3) DK2358674T3 (pt)
ES (3) ES2396583T3 (pt)
HK (3) HK1160448A1 (pt)
HR (3) HRP20120897T1 (pt)
IL (2) IL212230A (pt)
MX (3) MX2011005088A (pt)
MY (2) MY151211A (pt)
NZ (2) NZ592543A (pt)
PL (3) PL2358675T3 (pt)
PT (3) PT2358674E (pt)
RU (2) RU2515612C2 (pt)
SG (1) SG171311A1 (pt)
SI (3) SI2358676T1 (pt)
SM (3) SMT201200063B (pt)
TW (3) TWI461407B (pt)
WO (3) WO2010056938A1 (pt)
ZA (1) ZA201103495B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009313951B2 (en) 2008-11-14 2015-03-12 Theravance Biopharma R&D Ip, Llc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CA2794127A1 (en) 2010-04-22 2011-10-27 Theravance, Inc. Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
IL288194B2 (en) * 2016-08-30 2024-03-01 Theravance Biopharma R& D Ip Llc [- 2 (- 6,4,2--trifluorophenoxymethyl) phenyl[piperidine for use in the treatment of neurogenic hypotension on standing
JP7252978B2 (ja) 2018-06-01 2023-04-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ２－（１－（ｔｅｒｔ－ブトキシカルボニル）ピペリジン－４－イル）安息香酸を調製するためのプロセス
US20230372318A1 (en) 2022-03-28 2023-11-23 Theravance Biopharma R&D Ip, Llc Methods for treating a subject having multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
AU763356C (en) * 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
PL1635828T3 (pl) 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
MXPA05013960A (es) 2003-06-17 2006-02-24 Pfizer Nuevos compuestos.
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
US20070105870A1 (en) 2004-01-13 2007-05-10 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
US20070072859A1 (en) 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
CN101506164A (zh) 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
EP2068867A2 (en) * 2006-09-27 2009-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
AU2009313951B2 (en) 2008-11-14 2015-03-12 Theravance Biopharma R&D Ip, Llc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
IL288194B2 (en) * 2016-08-30 2024-03-01 Theravance Biopharma R& D Ip Llc [- 2 (- 6,4,2--trifluorophenoxymethyl) phenyl[piperidine for use in the treatment of neurogenic hypotension on standing

Also Published As

Publication number Publication date
BRPI0921596B1 (pt) 2021-10-26
US9162982B2 (en) 2015-10-20
CL2011001088A1 (es) 2011-10-14
EP2358674B1 (en) 2013-01-02
CA2739992C (en) 2016-09-20
HK1160449A1 (en) 2012-08-17
US20140045892A1 (en) 2014-02-13
IL212452A0 (en) 2011-06-30
EP2358675B1 (en) 2012-10-03
WO2010056939A1 (en) 2010-05-20
TW201022206A (en) 2010-06-16
CY1113855T1 (el) 2016-07-27
BRPI0921593B8 (pt) 2021-05-25
US10206913B2 (en) 2019-02-19
CN102216272B (zh) 2014-02-05
TWI441810B (zh) 2014-06-21
SMT201200063B (it) 2013-01-14
MX2011005089A (es) 2011-07-29
RU2515612C2 (ru) 2014-05-20
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
US20200000792A1 (en) 2020-01-02
US8592596B2 (en) 2013-11-26
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
CA2742105A1 (en) 2010-05-20
TWI443087B (zh) 2014-07-01
HRP20120920T1 (hr) 2013-01-31
EP2358675A1 (en) 2011-08-24
BRPI0921595B1 (pt) 2020-10-13
JP2012508759A (ja) 2012-04-12
JP2012508760A (ja) 2012-04-12
US20180050024A1 (en) 2018-02-22
HK1160448A1 (en) 2012-08-17
EP2358676A1 (en) 2011-08-24
US8304433B2 (en) 2012-11-06
AU2009313949A1 (en) 2010-05-20
US10946007B2 (en) 2021-03-16
PT2358675E (pt) 2012-12-12
AU2009313948B2 (en) 2015-03-12
US20160022660A1 (en) 2016-01-28
ES2397247T3 (es) 2013-03-05
JP5529150B2 (ja) 2014-06-25
US20100125093A1 (en) 2010-05-20
JP2014101384A (ja) 2014-06-05
MY151229A (en) 2014-04-30
AR114965A2 (es) 2020-11-11
CN102216272A (zh) 2011-10-12
CA2739992A1 (en) 2010-05-20
PL2358676T3 (pl) 2013-03-29
SMT201200065B (it) 2013-03-08
BRPI0921593A2 (pt) 2015-08-18
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
EP2358676B1 (en) 2012-10-10
US11723900B2 (en) 2023-08-15
US20140057944A1 (en) 2014-02-27
JP5506813B2 (ja) 2014-05-28
JP2014098033A (ja) 2014-05-29
RU2503662C2 (ru) 2014-01-10
US20230201181A1 (en) 2023-06-29
IL212230A0 (en) 2011-06-30
EP2358675B9 (en) 2019-09-11
US11596624B2 (en) 2023-03-07
PL2358675T3 (pl) 2013-03-29
CA2742114C (en) 2016-09-13
MY151211A (en) 2014-04-30
US10946006B2 (en) 2021-03-16
SI2358674T1 (sl) 2013-04-30
CA2742105C (en) 2016-09-13
US9187423B2 (en) 2015-11-17
HRP20130300T1 (hr) 2013-04-30
CA2742114A1 (en) 2010-05-20
HK1160452A1 (en) 2012-08-17
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
TWI461407B (zh) 2014-11-21
US20130030020A1 (en) 2013-01-31
CO6361993A2 (es) 2012-01-20
US20180289687A1 (en) 2018-10-11
TW201024264A (en) 2010-07-01
JP5598798B2 (ja) 2014-10-01
KR20110082197A (ko) 2011-07-18
PT2358674E (pt) 2013-03-05
HRP20120897T1 (hr) 2012-12-31
DK2358674T3 (da) 2013-04-08
AR074350A1 (es) 2011-01-12
CY1113622T1 (el) 2016-06-22
US10226454B2 (en) 2019-03-12
KR101656339B1 (ko) 2016-09-09
US20100125141A1 (en) 2010-05-20
EP2358674A1 (en) 2011-08-24
US20200316048A1 (en) 2020-10-08
BRPI0921595B8 (pt) 2021-05-25
US10722504B2 (en) 2020-07-28
CN102209712A (zh) 2011-10-05
US9675599B2 (en) 2017-06-13
MX2011005090A (es) 2011-09-06
ES2396583T3 (es) 2013-02-22
US20190142816A1 (en) 2019-05-16
CL2011001093A1 (es) 2011-09-02
KR101685186B1 (ko) 2016-12-09
SMT201300033B (it) 2013-05-06
AR074128A1 (es) 2010-12-22
US20140323735A1 (en) 2014-10-30
US20200316047A1 (en) 2020-10-08
CN102209712B (zh) 2016-04-06
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
KR101656338B1 (ko) 2016-09-09
TW201024263A (en) 2010-07-01
SI2358676T1 (sl) 2013-01-31
RU2011123875A (ru) 2012-12-20
US10034870B2 (en) 2018-07-31
AU2009313948A1 (en) 2010-05-20
US10441579B2 (en) 2019-10-15
PL2358674T3 (pl) 2013-06-28
DK2358676T3 (da) 2013-01-14
IL212230A (en) 2014-12-31
AU2009313949B2 (en) 2015-03-19
US8604058B2 (en) 2013-12-10
MX2011005088A (es) 2011-06-01
WO2010056941A1 (en) 2010-05-20
CO6361988A2 (es) 2012-01-20
US20130030185A1 (en) 2013-01-31
JP2012508761A (ja) 2012-04-12
CN102216271B (zh) 2013-09-25
US20180055830A1 (en) 2018-03-01
RU2011123890A (ru) 2012-12-20
JP2014139209A (ja) 2014-07-31
SI2358675T1 (sl) 2013-01-31
US20120277438A1 (en) 2012-11-01
KR20110082085A (ko) 2011-07-15
ES2401224T3 (es) 2013-04-17
PT2358676E (pt) 2012-12-06
DK2358675T3 (da) 2013-01-14
US10576073B2 (en) 2020-03-03
KR20110082196A (ko) 2011-07-18
AU2009313951B2 (en) 2015-03-12
BRPI0921593B1 (pt) 2021-05-04
US9073859B2 (en) 2015-07-07
ZA201103495B (en) 2012-01-25
AU2009313951A1 (en) 2010-05-20
NZ592543A (en) 2013-02-22
US20190134019A1 (en) 2019-05-09
US20160184288A1 (en) 2016-06-30
US8247433B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
SMT201600275B (it) Composti eterociclici utili come inibitori di pdk1
BRPI0918045A2 (pt) compostos de carboxamida heterocíclicos
BRPI0906705A2 (pt) Composto heterocíclicos
SMT201400010B (it) Purificazione di 1-[2-(2,4-dimetilfenilsolfanil)fenilÜpiperazin a
DK3564240T3 (da) Piperidinmellemprodukter
DK2300459T3 (da) Nye fenylpyrazinoner som kinasehæmmere
DK2610258T3 (da) Substituerede piperidindihydrothienopyrimidiner
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0914775A2 (pt) compostos de fenila dissubstituídos
DE502008003324D1 (de) Heteroaryl-substituierte piperidine
SMT201600031B (it) Composti eterociclici di fenossimetile
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
BR112012002336A2 (pt) compostos aza-heterocíclicos
PT2167085E (pt) Novas utilizações terapêuticas de 4-[2-(4- metilfenilsulfanil)fenil]piperidina
JP2009543766A5 (ja) ｍＰＧＥｓ−１阻害剤としての２−アリールインドール誘導体
DK2262486T3 (da) Quetiapin sammensætning
DE602007012260D1 (de) Nitratester von piperidinen
ATE514685T1 (de) Herbizid wirksame 4- (3-aminobenzoyl) -5- cyclopropylisoxazole
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]
BR112012003603A2 (pt) [4-(5-aminometil-fenil)-piperidin-1il]-1hindol-3-il]-metanonas dissubstituídas
BRPI0913396A2 (pt) compostos de piperidina 3- ou 4-substituídos
DK2181990T3 (da) Piperidinderivat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.